Log in to save to my catalogue

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemo...

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemo...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1eec0ffc35d244c397d164368ed31c3d

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study

About this item

Full title

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study

Publisher

United States: John Wiley & Sons, Inc

Journal title

Cancer medicine (Malden, MA), 2016-11, Vol.5 (11), p.3272-3281

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Cetuximab improves efficacy when added to chemotherapy for metastatic colorectal cancer (mCRC). Effective management of skin reactions from cetuximab improves quality of life (QoL), and treatment compliance in clinical trials. No data are available from real‐world settings. The ObservEr observational, multicenter, prospective study evaluated QoL, t...

Alternative Titles

Full title

Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in KRAS wild‐type metastatic colorectal cancer patients: the ObservEr Study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_1eec0ffc35d244c397d164368ed31c3d

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1eec0ffc35d244c397d164368ed31c3d

Other Identifiers

ISSN

2045-7634

E-ISSN

2045-7634

DOI

10.1002/cam4.888

How to access this item